



POWERING THE IMMUNE SYSTEM  
TO TRANSFORM LIVES

NEWS RELEASE

# Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

2024-10-03

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET.

A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at [www.vir.bio](http://www.vir.bio) and will be archived there for 30 days.

## About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir's clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs. Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir routinely posts information that may be important to investors on its website.

## Media

Arran Attridge

Senior Vice President, Corporate Communications

**aattridge@vir.bio**

## Investors

Richard Lepke

Senior Director, Investor Relations

**rlepke@vir.bio**

Source: Vir Biotechnology, Inc.